

# THE LANCET

## **Supplementary appendix**

This appendix formed part of the original submission. We post it as supplied by the authors.

Supplement to: Sisa I, Noblecilla E, Orozco F. Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs. *Lancet* 2021; published online Feb 19. [http://dx.doi.org/10.1016/S0140-6736\(21\)00357-3](http://dx.doi.org/10.1016/S0140-6736(21)00357-3).




Figure 1. Confirmed number of doses purchased by country income level classification. Data and figure are used with the permission of the Duke Global Health Innovation Center<sup>1</sup>

1 Duke Global Health Innovation Center. Launch and scale speedometer.

<https://launchandscalefaster.org/COVID-19> (accessed Jan 30, 2021).